Pathogenic ARH3 mutations result in ADP-ribose chromatin scars during DNA strand break repair.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 07 2020
Historique:
received: 29 01 2020
accepted: 08 06 2020
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 9 9 2020
Statut: epublish

Résumé

Neurodegeneration is a common hallmark of individuals with hereditary defects in DNA single-strand break repair; a process regulated by poly(ADP-ribose) metabolism. Recently, mutations in the ARH3 (ADPRHL2) hydrolase that removes ADP-ribose from proteins have been associated with neurodegenerative disease. Here, we show that ARH3-mutated patient cells accumulate mono(ADP-ribose) scars on core histones that are a molecular memory of recently repaired DNA single-strand breaks. We demonstrate that the ADP-ribose chromatin scars result in reduced endogenous levels of important chromatin modifications such as H3K9 acetylation, and that ARH3 patient cells exhibit measurable levels of deregulated transcription. Moreover, we show that the mono(ADP-ribose) scars are lost from the chromatin of ARH3-defective cells in the prolonged presence of PARP inhibition, and concomitantly that chromatin acetylation is restored to normal. Collectively, these data indicate that ARH3 can act as an eraser of ADP-ribose chromatin scars at sites of PARP activity during DNA single-strand break repair.

Identifiants

pubmed: 32636369
doi: 10.1038/s41467-020-17069-9
pii: 10.1038/s41467-020-17069-9
pmc: PMC7341855
doi:

Substances chimiques

Chromatin 0
Histones 0
X-ray Repair Cross Complementing Protein 1 0
XRCC1 protein, human 0
Adenosine Diphosphate Ribose 20762-30-5
Glycoside Hydrolases EC 3.2.1.-
ADPRS protein, human EC 3.2.1.143

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3391

Subventions

Organisme : Cancer Research UK
ID : C35050/A22284
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : T32 GM008666
Pays : United States
Organisme : Wellcome Trust
ID : 210634
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P010121/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101794
Pays : United Kingdom

Références

Azarm, K. & Smith, S. Nuclear PARPs and genome integrity. Gene Dev. 34, 285–301 (2020).
pubmed: 32029453
Chaudhuri, A. R. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610–621 (2017).
Hanzlikova, H. & Caldecott, K. W. Perspectives on PARPs in S phase. Trends Genet. 35, 412–422 (2019).
pubmed: 31036342
Feng, X. & Koh, D. W. Roles of poly(ADP-ribose) glycohydrolase in DNA damage and apoptosis. Int. Rev. Cel. Mol. Biol. 304, 227–281 (2013).
Davidovic, L., Vodenicharov, M., Afar, E. B. & Poirier, G. G. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp. Cell Res. 268, 7–13 (2001).
pubmed: 11461113
Abplanalp, J. et al. Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase. Nat. Commun. 8, 2055 (2017).
pubmed: 29234005 pmcid: 5727137
Fontana, P. et al. Serine ADP-ribosylation reversal by the hydrolase ARH3. elife 6, 861 (2017).
Oka, S., Kato, J. & Moss, J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 281, 705–713 (2006).
pubmed: 16278211
Sharifi, R. et al. Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J. 32, 1225–1237 (2013).
pubmed: 23481255 pmcid: 3642678
Caldecott, K. XRCC1 protein; form and function. DNA Repair 81, 102664 (2019).
pubmed: 31324530
Hanzlikova, H., Gittens, W., Krejcikova, K., Zeng, Z. & Caldecott, K. W. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res. 45, 2546–2557 (2016).
pmcid: 5389470
Caldecott, K. W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 9, 619–631 (2008).
pubmed: 18626472
Yoon, G. & Caldecott, K. W. Nonsyndromic cerebellar ataxias associated with disorders of DNA single-strand break repair. Handb. Clin. Neurol. 155, 105–115 (2018).
pubmed: 29891053
O’Connor, E. et al. Mutations in XRCC1 cause cerebellar ataxia and peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry 89, 1230–1232 (2018).
pubmed: 29472272 pmcid: 6227798
Hoch, N. C. et al. XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia. Nature 541, 87–91 (2016).
pubmed: 28002403 pmcid: 5218588
Komulainen, E. et al. Poly(ADP-ribose) polymerase-1 hyperactivity at DNA single-strand breaks triggers seizures and shortened lfespan. Biorxiv https://doi.org/10.1101/431916 (2018).
Ghosh, S. G. et al. Biallelic mutations in ADPRHL2, encoding ADP-ribosylhydrolase 3, lead to a degenerative pediatric stress-induced epileptic ataxia syndrome. Am. J. Hum. Genet. 103, 431–439 (2018).
pubmed: 30100084 pmcid: 6128219
Danhauser, K. et al. Bi-allelic ADPRHL2 mutations cause neurodegeneration with developmental delay, ataxia, and axonal neuropathy. Am. J. Hum. Genet. 103, 817–825 (2018).
pubmed: 30401461 pmcid: 6218634
Mashimo, M. et al. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells. JCI Insight 4, 14902 (2019).
Mashimo, M., Kato, J. & Moss, J. ADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stress. Proc. Natl Acad. Sci. USA 110, 18964–18969 (2013).
pubmed: 24191052
Fisher, A. E. O., Hochegger, H., Takeda, S. & Caldecott, K. W. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol. Cell Biol. 27, 5597–5605 (2007).
pubmed: 17548475 pmcid: 1952076
Caldecott, K. W. Protein ADP-ribosylation and the cellular response to DNA strand breaks. DNA Repair 19, 108–113 (2014).
pubmed: 24755000
El-Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic acids Res. 31, 5526–5533 (2003).
pubmed: 14500814 pmcid: 206461
Breslin, C. et al. The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function. Nucleic Acids Res. 43, 6934–6944 (2015).
pubmed: 26130715 pmcid: 4538820
Niere, M. et al. ADP-ribosylhydrolase 3 (ARH3), not poly(ADP-ribose) glycohydrolase (PARG) isoforms, is responsible for degradation of mitochondrial matrix-associated poly(ADP-ribose). J. Biol. Chem. 287, 16088–16102 (2012).
pubmed: 22433848 pmcid: 3351285
Gibson, B. A., Conrad, L. B., Huang, D. & Kraus, W. L. Generation and characterization of recombinant antibody-like ADP-ribose binding proteins. Biochemistry 56, 6305–6316 (2017).
pubmed: 29053245 pmcid: 6465537
Jungmichel, S. et al. Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol. Cell 52, 272–285 (2013).
pubmed: 24055347
Leidecker, O. et al. Serine is a new target residue for endogenous ADP-ribosylation on histones. Nat. Chem. Biol. 12, 998–1000 (2016).
pubmed: 27723750 pmcid: 5113755
Palazzo, L. et al. Serine is the major residue for ADP-ribosylation upon DNA damage. elife 7, e34334 (2018).
pubmed: 29480802 pmcid: 5837557
Hanzlikova, H. et al. The importance of poly(ADP-Ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol. Cell 71, 319–331 (2018).
pubmed: 29983321 pmcid: 6060609
Lehtiö, L. et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52, 3108–3111 (2009).
pubmed: 19354255
Sedelnikova, O. A. et al. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat. Res. Rev. Mutat. Res. 704, 152–159 (2010).
Bartlett, E. et al. Interplay of histone marks with serine ADP-ribosylation. Cell Rep. 24, 3488–3502.e5 (2018).
pubmed: 30257210 pmcid: 6172693
Liszczak, G., Diehl, K. L., Dann, G. P. & Muir, T. W. Acetylation blocks DNA damage-induced chromatin ADP-ribosylation. Nat. Chem. Biol. 14, 837–840 (2018).
pubmed: 30013063 pmcid: 6505472
Polo, L. M. et al. Efficient single-strand break repair requires binding to both poly(ADP-Ribose) and DNA by the central BRCT domain of XRCC1. Cell Rep. 26, 573–581.e5 (2019).
pubmed: 30650352 pmcid: 6334254
Breslin, C. et al. Measurement of chromosomal DNA single-strand breaks and replication fork progression rates. Methods Enzymol. 409, 410–425 (2006).
pubmed: 16793415
Grundy, G. J. et al. PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2). Nat. Commun. 7, 12404 (2016).
pubmed: 27530147 pmcid: 4992063
Baker, J., Faustoferri, R. & Quivery R. G. A modified chromogenic assay for determination of the ratio of free intracellular NAD+/NADH in Streptococcus mutans. Bio Protoc. 6, 1–9 (2016).
Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2017).
pmcid: 5753206
Kim, I.-K., Stegeman, R. A., Brosey, C. A. & Ellenberger, T. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 290, 3775–3783 (2015).
pubmed: 25477519
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general-purpose program for assigning sequence reads to genomic features. Bioinform Oxf. Engl. 30, 923–930 (2013).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Biorxiv https://doi.org/10.1101/002832 (2014).
Stephens, M. False discovery rates: a new deal. Biostatistics https://doi.org/10.1093/biostatistics/kxw041 (2016).
Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
pubmed: 20132535 pmcid: 2872874

Auteurs

Hana Hanzlikova (H)

Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic. hana.hanzlikova@img.cas.cz.
Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, UK. hana.hanzlikova@img.cas.cz.

Evgeniia Prokhorova (E)

Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

Katerina Krejcikova (K)

Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic.

Zuzana Cihlarova (Z)

Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic.

Ilona Kalasova (I)

Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic.

Jan Kubovciak (J)

Department of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic.

Jana Sachova (J)

Department of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic.

Richard Hailstone (R)

Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, UK.

Jan Brazina (J)

Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, UK.

Shereen Ghosh (S)

Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA, 92093, USA.
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, CA, 92123, USA.

Sebahattin Cirak (S)

Center for Molecular Medicine Cologne, University of Cologne, Cologne, 50931, Germany.
Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany.
Center for Rare Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany.

Joseph G Gleeson (JG)

Laboratory for Pediatric Brain Disease, Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA, 92093, USA.
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, CA, 92123, USA.

Ivan Ahel (I)

Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

Keith W Caldecott (KW)

Department of Genome Dynamics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, 142 20, Czech Republic. k.w.caldecott@sussex.ac.uk.
Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, UK. k.w.caldecott@sussex.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH